Skip to main content
WI

www.immunique.kr

Immunique develops cell-based therapeutics utilizing regulatory T cells from cord blood to treat autoimmune diseases and cancer. By maximizing the functionality of these pure cells, the company aims to restore immune balance and address the challenges posed by chronic, incurable conditions.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Current treatments for autoimmune diseases and cancer often fail to fully restore immune balance, leading to chronic conditions and significant side effects. Existing cell-based therapies may lack the purity and functionality needed to effectively regulate the immune system and address the underlying causes of these diseases.

Solution

Immunique develops advanced cell-based therapeutics using highly purified regulatory T cells (Tregs) derived from cord blood to treat autoimmune diseases and cancer. By maximizing the functionality of these Tregs, Immunique aims to restore immune balance and address the limitations of existing treatments. Their approach focuses on developing innovative therapies that can effectively modulate the immune system, offering potential solutions for chronic and incurable conditions. The company's pipeline includes treatments for Graft-versus-Host Disease (GvHD), Aplastic Anemia (AA), and other autoimmune disorders.

Target Audience

The primary target audience includes patients suffering from autoimmune diseases such as Graft-versus-Host Disease and Aplastic Anemia, as well as those with cancers where immune modulation can play a therapeutic role.

Features

  • Treg cell therapy leveraging the unique properties of regulatory T cells derived from cord blood.
  • IMQ101-GvHD: A therapeutic for Graft-versus-Host Disease targeting the T cells that attack the patient's normal cells after allogeneic hematopoietic stem cell transplantation.
  • IMQ101-AA: A treatment for Aplastic Anemia, addressing the autoimmune destruction of bone marrow.
  • IMQ301/302: Therapies targeting various autoimmune diseases by modulating the immune system to prevent it from attacking the body's own tissues.
This profile is AI-generated and may contain inaccuracies.